Pharmafile Logo
Pharmafocus logo
Advanced Search

breast cancer

Showing 15 posts of 167 posts found.

Roche’s Tecentriq improves pathological complete response in triple-negative breast cancer at Phase 3

June 19, 2020
Medical Communications, Research and Development Cancer, Genentech, Roche, breast cancer, tecentriq

 

News
lilly_building_with_american_flag_web

Lilly’s Verzenio combo tops Pfizer’s Ibrance and is first CDK4/6 inhibitor to show benefit in HR+,HER2- early breast cancer

June 18, 2020
Research and Development Eli Lilly, Pfizer, Verzenio, breast cancer, ibrance

 

News

NICE gives thumbs-up to Roche’s Kadcyla in HER2+ breast cancer sub-population

May 7, 2020
Sales and Marketing Cancer, Kadcyla, NHS, NICE, Roche, UK, breast cancer

NICE has revealed that it has recommended the NHS use of Roche’s Kadcyla (trastuzumab emtansine) for HER2+ breast cancer in …

News

FDA approves Immunomedics’ Trodelvy for metastatic triple-negative breast cancer one month ahead of schedule

April 23, 2020
Sales and Marketing Cancer, Immunomedics, Trodelvy, breast cancer, pharma

Immunomedics has scored approval with the FDA for Trodelvy (sacituzumab govitecan-hziy) in the treatment of metastatic triple-negative breast cancer, it …

News

Prostate Cancer becomes most commonly diagnosed cancer in England

January 28, 2020
Manufacturing and Production Cancer, Cancer diagnoses, NHS England, breast cancer, prostate cancer

Prostate cancer has overtaken breast cancer to be the most commonly diagnosed cancer for the first time in England, latest …

News

China approves Roche cancer drug Kadcyla

January 22, 2020
Business Services China, Roche, breast cancer, cancer treatment, oncology

China has approved the import of Roche’s drug for breast cancer, just after it recently won expanded approval in the …

News
42271822770_6d2a1d533f_b

AI is more accurate than doctors at diagnosing breast cancer, study finds

January 2, 2020
Business Services AI, AI Cancer, AI Trials, AI diagnoses, AI in clinical trials, Cancer, breast cancer

A recent study showed that Artificial Intelligence is more accurate than doctors in diagnosing breast cancer from mammograms. The research …

News
astrazeneca_sign_sky

FDA gives accelerated approval to AstraZeneca and Daiichi’s breast cancer drug

December 23, 2019
Sales and Marketing AstraZeneca, Breast Cancer drug, Cancer, breast cancer, skin cancer

The FDA has approved the breast cancer drug Enhertu, developed by AstraZeneca and Daiichi Sankyo. José Basel, the Executive Vice …

News
astrazeneca_plaque

AstraZeneca sells Amrimidx and Casodex European rights to Juvisé Pharmaceuticals

December 20, 2019
Medical Communications AstraZeneca, Cancer, Juvise, breast cancer, prostate cancer

AstraZeneca has announced that it has agreed to sell the rights to Arimidex (anastrozole) and Casodex (bicalutamide) in Europe, as …

News
roche

Roche’s subcutaneous Perjeta/Herceptin combo proves non-inferior to IV formulation in HER2-positive early breast cancer

December 12, 2019
Research and Development Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma

New Phase 3 data from Roche has shown that its subcutaneously-delivered formulation of Perjeta (pertuzumab) and Herceptin (trastuzumab), in combination …

News
pfizer_building_logo1_19

Pfizer’s Ibrance approved by NICE, to be added to the Cancer Drugs Fund

November 28, 2019
Manufacturing and Production, Research and Development Cancer Drugs Fund, NHS, NICE, Pfizer, breast cancer, ibrance, pharma

Today it was announced that the National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Ibrance (palbociclib) to …

News

Novartis’ Kisqali approved for NHS Scotland in most common advanced breast cancer

November 12, 2019
Manufacturing and Production, Sales and Marketing Cancer, Kisqali, NHS, Novartis, Scotland, breast cancer, pharma

NHS patients in Scotland will soon be able to access Novartis’ CDK4/6 inhibitor Kisqali (ribociclib) after the Scottish Medicines Consortium …

News
rocherooflr

NICE rejects Roche’s immunotherapy Tecentriq in unresectable metastatic triple A breast cancer

October 3, 2019
Sales and Marketing Cancer, NICE, Roche, breast cancer, pharma, tecentriq

NICE has revealed its decision not to approve Roche’s immunotherapy Tecentriq (atezolizumab) for use on the NHS in England and …

News
roche__tree

Roche’s Tecentriq plus chemo shows promise in first-line, advanced bladder cancer

October 1, 2019
Manufacturing and Production, Research and Development Cancer, ESMO 2019, Roche, breast cancer, pharma, tecentriq

Roche has revealed data from an interim analysis of its immunotherapy Tecentriq (atezolizumab) at the 2019 European Society for Medical …

News
shutterstock

Age affects efficacy of immunotherapy treatments in breast cancer patients

September 9, 2019
Research and Development, Sales and Marketing Cancer, breast cancer, pharma

Recent clinical trial data has shown that immune checkpoints blockade (ICB) therapy, designed to unleash a patient’s immune system to …

News

Latest content

FDA grants marketing authorisation to DNA test for predisposition to certain cancers

October 2, 2023

Biogen’s biosimilar Tofidence approved by FDA

October 2, 2023

Austrian state secretary to speak at FlyPharma Europe 2023

September 29, 2023

Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

September 29, 2023

Kura Oncology shares preclinical data for NSCLC treatment

September 29, 2023